Purwanto Bambang, Prasetyo Diding H
Department of Internal Medicine, Faculty of Medicine, University of Sebelas Maret - Moewardi Hospital. Jl. Kolonel Sutarto 132, Surakarta, Indonesia.
Acta Med Indones. 2012 Apr;44(2):140-4.
to determine the effect of oral N-acetylcysteine (NAC) on plasma levels of inflammatory markers in Continuous Ambulatory Peritoneal Dialysis (CAPD) patients.
we performed a placebo-controlled study over 8 weeks in 32 patients on regular CAPD. The patients were divided into 2 groups of 16 patients matched for age and gender. The first group was given NAC 2x600 mg/day for 8 weeks and inflammatory parameter was compared with control group. The immune system is determined from the average levels of Procalcitonin, IL-6, IL-1, C3, SICAM, hsCRP, and TNF- before and after treatment with NAC. Student t-test was performed to compare the means between NAC receiving and control groups. All statistics were done using SPSS software (SPSS Ver 16.0).
administration of NAC, significantly diminished PCT (-0.38±0.57 vs 0.09±0.14; p=0.004), IL-6 (-1.94±3.03 vs 1.19±1.99; p=0.002), IL-1 (-0.14±0.21 vs 0.01±0.04; p=0.010), C3 (-7.40±12.04 vs 4.60±8.12; p=0.002), sICAM (-80.59±29.18 vs -35.02±46.99; p=0.007), hsCRP (-1.50±1.32 vs 0.81±1.17; p<0.001) and TNF- (-0.73±0.47 vs 0.14±0.74; p<0.001) levels compared control to group.
short-term oral NAC treatment resulted in reduction of circulating PCT, IL-6, IL-1, C3, sICAM, hsCRP, and TNF- in CAPD patients.
确定口服N-乙酰半胱氨酸（NAC）对持续性非卧床腹膜透析（CAPD）患者血浆炎症标志物水平的影响。
我们对32例接受常规CAPD治疗的患者进行了为期8周的安慰剂对照研究。患者按年龄和性别匹配分为两组，每组16例。第一组给予NAC 2×600mg/天，共8周，并将炎症参数与对照组进行比较。通过治疗前后降钙素原、IL-6、IL-1、C3、可溶性细胞间黏附分子-1（sICAM）、高敏C反应蛋白（hsCRP）和肿瘤坏死因子-α（TNF-α）的平均水平来评估免疫系统。采用学生t检验比较接受NAC治疗组和对照组之间的均值。所有统计分析均使用SPSS软件（SPSS 16.0版）完成。
与对照组相比，给予NAC后，降钙素原（-0.38±0.57 vs 0.09±0.14；p = 0.004）、IL-6（-1.94±3.03 vs 1.19±1.99；p = 0.002）、IL-1（-0.14±0.21 vs 0.01±0.04；p = 0.010）、C3（-7.40±12.04 vs 4.60±8.12；p = 0.002）、sICAM（-80.59±29.18 vs -35.02±46.99；p = 0.007）、hsCRP（-1.50±1.32 vs 0.81±1.17；p < 0.001）和TNF-α（-0.73±0.47 vs 0.14±0.74；p < 0.001）水平显著降低。
短期口服NAC治疗可降低CAPD患者循环中的降钙素原、IL-6、IL-1、C3、sICAM、hsCRP和TNF-α水平。
